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Dongxian Jiang1†, Deming He1†, Yingyong Hou1*, Weiqi Lu2*, Yuan Shi1, Qin Hu1, Shaohua Lu1, Chen Xu1,
Yalan Liu1, Ju Liu1, Yunshan Tan1 and Xiongzeng Zhu3Abstract: Intra-abdominal fibromatosis (IAF) commonly develops in patients who had abdominal surgery. In rare
instances, it occurs subsequent to gastrointestinal stromal tumor (GIST). This special situation has clinical significance in
imatinib era. About 1000 patients with GIST in our institution from 1993 to 2010 were re-evaluated based on their
clinical and pathological data, the treatment strategies and the follow-up information. We identified 2 patients who
developed IAF after GIST resection. Patient 1 was a 54 year-old male and had 5 cm × 4.5 cm × 3.5 cm jejunal GIST
excised on February 22, 1994. Three years later, an abdominal mass with 7 cm × 6 cm × 3 cm was identified. He was
diagnosed as recurrent GIST from clinical point of view. After excision, the second tumor was confirmed to be IAF.
Patient 2 was a 45-year-old male and had 6 cm × 4 cm × 3 cm duodenal GIST excised on August 19, 2008. One year
later, a 4 cm mass was found at the original surgical site. The patient refused to take imatinib until the tumor increased
to 8 cm six months later. The tumor continued to increase after 6 months’ imatinib therapy, decision of surgical
resection was made by multidisciplinary team. The second tumor was confirmed to be IAF with size of 17 cm ×
13 cm × 11 cm. Although IAF subsequent to GIST is very rare, it is of clinical significance in imatinib era as an
influencing factor for making clinical decision.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1076715989961803
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Gastrointestinal stromal tumor (GIST) is the most com-
mon gastrointestinal mesenchymal tumor and mainly
treated with surgical resection in the past era without ef-
fective drugs. The identification of KIT mutations in re-
cent years has led to the development of specific, targeted
therapies with tyrosine kinase inhibitors such as imatinib
mesylate (STI571, Gleevec; Novartis Pharmaceuticals,
Basel, Switzerland) and sunitinib malate (SU11248, Sutent;
Pfizer, Inc, New York, USA), which are more effective for
unresectable, metastatic and recurrent diseases [1].* Correspondence: houyingyong@hotmail.com; lu.weiqi@zs-hospital.sh.cn
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reproduction in any medium, provided the orWith the accumulation of knowledges on GIST and
long-time follow-up information, GIST patients are found
to simultaneously or metachronously have other types of
tumors [2-7], some of which are easier to be differentiated
from GIST [4,6], while others might be confused with re-
current GIST from the clinical point of view [2,3].
Intra-abdominal fibromatosis (IAF) is a rare mesenchy-
mal tumor which does not metastasize but tends to ex-
hibit a high degree of local infiltration and invasion, thus
becoming lethal in some cases [8-11]. IAF developed after
abdominal surgery and individual with both GIST and IAF
were reported recently [2,3] and non-random association
between GIST and IAF was established very recently based
on data from 10 medical centers [12].
In this report, we describe 2 additional GIST patients
who admitted to our institution before and after imatinib
era, respectively, and developed IAF at the site of GIST
resection beds. Both of the two cases created the firsttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Jiang et al. Diagnostic Pathology 2013, 8:125 Page 2 of 7
http://www.diagnosticpathology.org/content/8/1/125impression of GIST recurrence. Surgical excision of the le-
sion was done without any hesitation in the first patient,
however, difficult decision owing to the suspicion of meta-
static disease when imatinib therapy was available in the
second patient. These 2 cases highlight the importance of
recognizing the coexistence of other diseases in patients
with chronic GIST since the metachronous tumor subse-
quent to GIST is easy to be mis-regarded as recurrent




Medical records and tissue specimens of about 1375
primary mesenchymal tumors of GI tract with the years
ranging from 1993 to 2010 were retrieved from
Zhongshan Hospital, Fudan University. Among them,
1055 cases were primary mesenchymal tumors pre-
viously characterized as leiomyoma, leiomyosarcoma,
leiomyoblastoma, schwannoma, stromal or smooth muscle
tumors originated from GI tract. Out of these 1055 cases,
997 cases underwent surgery and immunohistochemically
or histologically identified as GISTs based on KIT po-
sitive immunohistochemical detection or histopatho-
logical spectrum with KIT-positive tissues. All tumor
slides were reviewed by two experienced pathologists.
Another 195 GIST patients were collected from our
own consultant files from January 2003 to March 2010.
Tumor tissue collection and the following analyses were
approved by the review boards of Zhongshan Hospital,
Fudan University.
Clinical records
Patient demographics and clinical data were retrieved
from the medical records. Data on gender, age at diagno-
sis, KIT, PDGFRA mutation status and follow-up infor-
mation were collected.
Histological evaluation
Hematoxylin and eosin (H&E)-stained slides for each
patient were reviewed and the following features were
recorded: predominant cell type, pleomorphism, nu-
clear atypia, necrosis, mitotic count, invasion, and risk
levels [13].
Immunohistochemical evaluation
Immunohistochemical staining was performed based on
the method previously reported [14]. Formalin-fixed par-
affin sections were prepared from one representative
block and subjected to immunohistochemical staining
with a panel of antibodies against CD117 (rabbit poly-
clonal anti-human KIT, diluted 1:150; Dako, Denmark),
CD34 (mouse monoclonal antibody, clone QBEnd 10,
diluted 1:200; Dako), α-smooth muscle actin (mousemonoclonal antibody, clone 1A4, diluted 1:200; Dako),
desmin (mouse monoclonal antibody, clone D33, diluted
1:200; Dako), S-100 protein (polyclonal, diluted 1:300;
Dako) and vimentin (mouse monoclone antibody, V9,
diluted 1:1000; Dako). The slides were first treated with
0.01M citrate buffer (pH 6.0) by microwave method for
antigen retrieval, and incubated overnight at 4°C.
Immunohistochemical detection was performed with
EnVision-based system using a commercial kit (Dako).
Diaminobenzidine was used as the chromogen, and all
sides were counterstained with hematoxylin.
Results
Report of two cases
Patient 1: A 54-year-old male admitted to Zhongshan
Hospital (Fudan University, Shanghai, China) on Feb 8th,
1994 due to tarry black stools for four months. Gastros-
copy found no abdominal changes. Mesenteric artery angi-
ography showed a jejunal tumor. Emission computerized
tomography (ECT) examination found active bleeding
near the junction of the jejunum and ileum. Primary im-
pression was small intestinal leiomyoma. The patient was
treated with radical resection of part of the jejunum.
Pathological examination found a non-mitotic submuco-
sae tumor with a small ulcer. The tumor was 5 cm ×
4.5 cm × 3.5 cm in size and showed outward growth pat-
tern. The primary diagnosis was cellular leiomyoma and
now reviewed as GIST based on morphology (Figure 1)
and immunohistochemical staining results, which showed
that the tumor cells were positive for CD117, but negative
for CD34, a-SMA, desmin and S-100. The patient was
classified into low risk level according to the current risk
level classification [15]. He recovered smoothly after sur-
gery and was disease free without any further therapy.
However, in Feb 1997, he admitted to our hospital again
due to back ache. Computed tomography (CT) scanning
showed a mass in the retroperitoneum of the right lower
quadrant. Since clinical impression was a recurrent tumor,
he was treated with laparotomy without any hesitation. A
lower right retroperitoneal tumor with partial small intes-
tine and partial ureter were successfully excised. Gross
examination found a 7 cm × 6 cm × 3 cm mass attached
to small intestine, and the ureter was entrapped in it. The
tumor sections were gray-white. Microscopical examin-
ation found spindle cells with abundant collagen, no de-
marcated boundary between the tumor cells and the
muscularis propria of jejunum (Figure 2), and no more
than 3 mitotic ureter cells per 50 high power fields. The
tumor was different from the primary tumor morpho-
logically. The tumor cells were negative for α-SMA, S-
100, desmin, CD34 and CD117. He was diagnosed to
have IAF after discussion with senior pathologists in
Department of Pathology, Cancer Hospital, Fudan uni-
versity since the situation was very rare in clinical
Figure 1 Characteristics of GIST showed spindle cells with intersecting growth pattern Hemotoxylin eosin staining 5 ×.
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two operations.
Patient 2: A 45-year-old male was found to have duo-
denal tumor by physical examination in Aug 2008. He was
treated with partial duodenal resection together with
tumor on Aug 19th, 2008 in a local hospital (Haining
County People’s Hospital, Zhejiang Province). The tumor
was 6 cm × 4 cm × 3 cm in size. Microscopical examin-
ation found non-mitotic, spindle cells with intersecting
growth pattern. The tumor cells were positive for CD117
and CD34, but negative for α-SMA, desmin and S-100 by
immunohistochemistry. He was diagnosed as GIST and
classified into moderate risk level. The patient was not
treated with any adjuvant therapy after the operation.
Twelve months later, a solitary and localized abdominalFigure 2 Histological images (1 ×) of the tumor. Hematoxylin-eosin stai
dilated thin-walled veins, 3) interwoven spindle cells and varying amounts
with intact mucosal layer.tumor with 4 cm in diameter was detected in the left
upper abdominal cavity in routine CT scanning. The pa-
tient was reluctant to treatment. Six months later, the
tumor was increased to 8 cm. He was initially treated with
imatinib (400 mg daily) on Mar 28th, 2010 since the first
clinical impression was recurrence of GIST. But CT scan
performed 3 months after initiation of imatinib therapy
found the tumor size was increased and CT scan
performed 6 months after initiation of imatinib therapy re-
vealed significant progression of the left abdominal tumor:
its size enlarged to 15 cm. At this point, the patient was
referred to our hospital for further management. A multi-
disciplinary team (MDT) meeting was convened. Physical
examination identified a huge palpable mass in the left
middle abdominal cavity. Abdominal ultrasonographyning showing 1) proliferating non-dysplastic fibroblasts, 2) prominent
of collagen, 4) tumor cells invading the muscle layer of the jejunum
Figure 3 Preoperative CT scan images of the tumor. A
contrast-enhanced CT image showing a homogeneous low-dense
tumor with slight enhancement involving the proximal jejunum
and descending colon.
Figure 4 The upper ureter entrapped in the inside of
the tumor.
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diameter. CT scan revealed a low-dense, homogeneous
tumor, mainly involving mesentery and mesenteric veins
and adjacent to jejunum and colon, the ureter was also en-
trapped in it (Figures 3 and 4). Angiography showed a
hypovascular tumor encroaching on superior mesenteric
artery and vein, and their branches. Urography found the
tumor obstructing the upper part of the left ureter, causing
left side hydronephrosis. Furthermore, the primary
duodenal GIST (Figure 5) was reevaluated as borderline
nature and no KIT and PDGFRA mutation was found in
the tumor. Therefore, a MDT decision was made to
resect the lesion surgically. Prior to surgery, detailed
examinations were performed. On Nov. 11th, 2010, theFigure 5 Histological images of the tumor with spindle cells and intepatient underwent exploratory laparotomy. The mesen-
teric tumor was successfully excised completely with
adherent tissues and organs. Laparotomy revealed a
hard tumor of 15 cm which appeared to originate from
jejunal mesentery, involving proximal jejunum and the
descending colon. The tumor also invaded and en-
trapped a segment of the upper part of ureter. The
involved parts of jejunum and the tumor-bearing jejunal
mesentery were resected en bloc along with the affected
part of the mesocolon and the left kidney and the
ureter. Grossly, the mass was resected with adequate
margins and measured as 17 cm × 13 cm × 11cm. On
section, the tumor was white and firm mass without
necrosis, cystic change and hemorrhage (Figure 6).
Microscopic examination of the tumor showed that non-
dysplastic fibroblasts proliferating in the jejunal mesentery
had infiltrated into the adjacent small intestine and ureterrsecting growth pattern Hemotoxylin eosin staining 5 ×.
Figure 6 Images of resected specimen, showing an
intra-abdominal tumor with sacrifice of partial resection of the
jejunum, colon, and left kidney in the small bowel mesentery
and its surface section appearance, which is white and
compact,and has no necrosis, hemorrhage or cystic changes.
The size of the tumor was 17 cm × 13 cm × 11 cm.
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CD34, a-SMA and desmin. Therefore, the lesion was diag-
nosed as a mesenteric IAF. The postoperative course was
uneventful without adjuvant therapy and no local recur-
rence has been noted as of October 2012.
Discussion
Fibromatosis is a group of fibroblastic or myofibroblastic
tissues that can be locally aggressive but do not
metastasize [16]. The incidence of desmoids tumor has
been reported as 2–4 cases per 1 million population,
and deep fibromatosis, such as those arising in the ab-
dominal cavity, are often referred to as IAF [17], whichFigure 7 Microscopic images of the tumor (5×), showing loosely arran
plump spindle cells with tapering ends, oval, vesicular nuclei, modera
vessels of varying calibers.accounts for 8% of fibromatosis [18]. Although rare, IAF
is the most common primary mesenteric tumor with
spindle cell morphology [19]. Its causes and underlying
mechanisms are unknown. Although most cases are
sporadic, about 20% cases are associated with familial
adenomatous polyposis (FAP) in a syndrome known as
Gardner syndrome [20], about 10% cases with abdom-
inal surgery or trauma experiences for various reasons
[17,21-24], and rare cases with prior radiation therapy
[25,26]. The two cases reported here were associated
with previous abdominal surgery for GIST.
Of the above-mentioned situations, IAF developed after
surgical resection for other tumors has special clinical sig-
nificance. IAF has been observed in the sites of previous
abdominal surgery for tumors [23,24]. Its diagnosis often
is difficult to establish preoperatively, and it is usually
misdiagnosed as recurrence at first clinical impression
[2,22,23,27]. Surgical excision of the lesion is a difficult de-
cision owing to the suspicion of metastasis mainly due to
the following reasons. 1) The appearance of IAF on con-
trast enhanced imaging is not specific, therefore, the
imaging diagnosis of IAF developed after abdominal
surgery for other tumors is very difficult except in patients
with familial adenomatous polyposis [20,28]. 2) The time
interval between surgery and development of fibromatosis
ranges from 2 months to several years (2.6 years on
average) [17], which overlaps with recurrent disease.
Recently, there have been prior several case reports
describing IAF arising on the site of a previously excised
GIST. In these cases, IAF was first misdiagnosed as GIST
recurrence [2,3]. Very recently, a non-random association
between GIST and IAF was described. However, it’s differ-
ent from a non-random association between GIST and
myeloid leukemia [4], since an accurate diagnosis couldged spindle cells with bland, oval nuclei and minimal cytoplasm,
te amounts of eosinophilic cytoplasm, and several thin-walled
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examination, as there are no typical imaging findings to
suggest a IAF. Although it is a very rare event, IAF devel-
oped synchronously or metachronously with GIST could
occur in most medical centers, for example, 28 IAF pa-
tients were collected from 10 medical centers [19].
Introduction of imatinib has greatly changed the clinical
approach to intra-abdominal stromal spindle cell tumors.
GIST is the most common mesenchymal tumor in gastro-
intestinal tract. Oncogenic mutations in KIT or PDGFRA
have been identified as central tumor-initiating events in
many GISTs [29]. Treatments with imatinib and sunitinib,
two small-molecule inhibitors of the mutant KIT and
PDGFRA receptor tyrosine kinases, significantly prolong
survival of patients with GIST [1]. The median time for
disease progression is 18–24 months in imatinib-treated
patients with unresectable GIST. The clinical decision has
been changed in patients with recurrent GIST.
In this study, the first patient had the disease in the era
before imatinib. Since GIST is resistant to conventional
cytotoxic chemotherapy [30], surgical resection was the
first option for the patients. The second patient had the
disease in the imatinib era, therefore, imatinib therapy was
the first recommendation. However, the patient was not
benefited from imatinib treatment: the tumor continued
to grow rapidly after six months of imatinib therapy. After
referred to our hospital, pathological re-evaluation sug-
gested that the primary GIST was of borderline nature
and the opportunity for recurrence was very low based on
our previous experiences [31,32]. Furthermore, mutations
in KIT and PDGFRA were not found in GIST. Since
imatinib is less effective against GIST without KIT or
PDGFRA mutation [33], and initial studies suggest that
sunitinib treatment rarely results in objective responses in
GIST [34,35], debulking surgery remains a recognized
standard practice in the case of local progression because
such procedure could prolong survival of patients who are
resistant or insensitive to imatinib treatment [36]. There-
fore, the decision of surgical resection was made for cure
and definite diagnosis after MDT discussion.
Surgical intervention for IAF is generally considered to
be the treatment of choice and is curative in many cases.
Some studies have reported better prognosis for IAF pa-
tients with non-Gardner’s-associated IAF than for those
complicated by Gardner’s syndrome [8,10,17,37]. In the
study, both patients had no family history of FAP and un-
eventful prognosis. Complete surgical resection remains
the cornerstone of management of IAF, while unresectable
or residual disease can be treated with multiple choices.
Nonsurgical treatment protocols mainly rely on sulindac
[28], toremifene [38], cytotoxic chemotherapy [39], or in
some circumstances, radiotherapy [40]. Each of them
has variable and unpredictable efficacy [28]. Therefore.
new treatment protocols for IAF are gradually beingrecommended, such as imatinib [41], sunitinib [42],
bevacizumab [43], or sorafenib [44]. However, the two
cases reported had been treated with imatinib at a dose of
400 mg for liver metastatic GIST. One achieved four years
of long-term stable control [3] and the other achieved 11
months of disease control [2], but both developed IAF in
primary GIST bed. The second patient was not benefit
from imatinib therapy at this dosage.
Mace et al. recommended imatinib treatment at dose
of 400 mg giving twice per day as a new therapeutic ap-
proach for desmoids tumor [45]. In Dumont’s cases, a
patient who received imatinib at 400 mg/day for gastric
GIST developed IAF on the posterior wall of the gastric
antrum 35 months after initial diagnosis. After in-
creasing imatinib dose to 800 mg/day, patient partially
responded to both tumors [12], suggesting that patients
with IAF might benefit from high dosage of imatinib.
Nevertheless, surgical trauma at the GIST excision site
may predispose to the development of the IAF. This situ-
ation broads differential diagnosis and elicits a range of
potential treatment options ranging from imatinib therapy
to aggressive surgical re-excision for IAF. An accurate
diagnosis is possible only after surgical removal and patho-
logical examination, as there are no typical imaging find-
ings to suggest IAF. Excluding diagnosis of recurrence of
GIST is crucial for further management of our patients
due to the increasing use of imatinib in the treatment of
advanced GIST. In rare instances as illustrated in our
cases, co-existence of another disease should be consid-
ered. The current two cases highlight the need for careful
consideration of IAF when a rapidly growing spindle cell
tumor is encountered in a post-GIST patient.
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